By: Vicki Moore, PhD From: cancertherapyadvisor.com It may be possible to safely omit chemotherapy for patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer, according to an updated analysis of the DETECT V study. Wolfgang Janni, MD, PhD, of the University Hospital Ulm in Ulm, Germany presented the findings at the San Antonio Breast Cancer Symposium 2025. The randomized, multicenter, …
Evolving Post–CDK4/6 Inhibitor Strategies Reflect Need for Precision Approaches in HR+ Breast Cancer
By: Courtney Flaherty From: onclive.com The treatment paradigm for hormone receptor–positive breast cancer post-CDK4/6 inhibition is entering a rapid state of evolution, reflecting the need for novel endocrine therapies and targeted agents that improve historically low survival outcomes for patients in the second-line setting and beyond, according to Kevin Kalinsky, MD, MS, FASCO. “How we’re treating patients in 2025 is …
Consistent Monitoring for ESR1 Mutations Essential in HR+, HER2- mBC
By: Tajuana Bradley, MS, FNP-BC From: oncnursingnews.com Supporting patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer as they move to the second line of therapy can be done in part by educating patients on adverse events (AEs) in advance and consistently testing patients for ESR1 mutations, said an expert. Following a Community Case Forum with Oncology Nursing News, moderator …
Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer
By: Silas Inman From: targetedonc.com Multiple novel agents with diverse mechanisms of action are currently in development to overcome resistance to endocrine therapy (ET) and CDK4/6 inhibitors in hormone receptor–positive breast cancer. This ongoing research, highlighted in a session by Hope S. Rugo, MD, at the 42nd Annual Miami Breast Cancer Conference, aims to address the significant unmet clinical need …
How Combining Drugs May Be More Effective at Treating HER2-Positive Breast Cancer
By: Tayler Shaw From: cuanschutz.edu When oncologist Elena Shagisultanova, MD, PhD, joined the University of Colorado Anschutz Medical Campus in 2015, she started working in a clinic to help young women with breast cancer. She soon noticed that certain types of breast cancer — called HER2-positive and HR-positive — were more common than expected. “I felt right away that the …
The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts
By: Ashling Wahner From: onclive.com Ongoing research may solidify the roles of oral selective estrogen receptor degraders (SERDs), PARP inhibitors, and additional targeted therapies, particularly after progression in CDK4/6 inhibitors, in the management of hormone receptor (HR)–positive breast cancer, according to Shipra Gandhi, MD. “We are living in an interesting era where we have multiple options available for patients [with …
Patient Selection Takes Priority as Standard of Cares Shift in HR+ and HER2+ Breast Cance
By: Ashling Wahner From: onclive.com With the array of CDK4/6 inhibitors available for patients with hormone receptor (HR)–positive breast cancer, treatment optimization according to patient characteristics is crucial, according to Lauren E. Nye, MD, who added that additional treatments are on the horizon for patients with brain metastases. In an interview with OncLive® following a State of the Science Summit™ …
Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer
By: Caroline Helwick From: ascopost.com Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to their pharmacokinetics or toxicity profiles, which allow for ligand-independent estrogen receptor signaling as a mechanism of resistance. Novel endocrine approaches to addressing treatment resistance, with a focus …
Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
By: Charles Bankhead From: medpagetoday.com The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us …
CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer
By: Ashling Wahner From: onclive.com Selection and sequencing of CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer hinge on the maturation of data in the first-line setting and beyond, and these decisions need to account for patient concerns and preferences, according to Sarah Sammons, MD. Primary results from the phase 3 SONIA trial (NCT03425838) demonstrated that …